A Phase IIIb, Multicentre, Randomised, Parallel-Group, Placebo-Controlled, Double-Blind Study to Investigate the Efficacy and Safety of OROS Hydromorphone in Subjects with Moderate-to-Severe Chronic Pain Induced by Osteoarthritis of the Hip or the Knee

Table 3

Concomitant analgesic medication use in the HOP trial (ITT population).

	Treatment
	OROS hydromorphone	Placebo	Total
NSAID, 𝑛 (%)
No	21 (15.22)	30 (22.13)	51 (17.77)
Yes	117 (84.78)	119 (79.87)	236 (82.23)
Total	138 (100)	149 (100)	287 (100)
Paracetamol, 𝑛 (%)
No	114 (82.61)	124 (83.22)	238 (82.93)
Yes	24 (17.39)	25 (16.78)	49 (17.07)
Total	138 (100)	149 (100)	287 (100)
Any analgesic, 𝑛 (%)
No	5 (3.62)	11 (7.38)	16 (5.57)
Yes	133 (96.38)	138 (92.62)	271 (94.43)
Total	138 (100)	149 (100)	287 (100)

ITT, intent-to-treat; NSAID, non-steroidal anti-inflammatory drug.